NRG-LU003 was a National Cancer Institute and NRG Oncology clinical trial designed to study clinical benefit of a 2nd or 3rd generation ALK inhibitor, MET inhibitor, or chemotherapy in patients who developed cancer progression on a second-generation ALK inhibitor. Treatment was to be assigned based on genetic changes identified on their tumor biopsy. NRG-LU003 was to compare a number of ALK inhibitors including lorlatinib, ceritinib, alectinib, brigatinib, and ensartinib, as well as crizotinib as MET/ALK inhibitor. Previous research had shown that these therapies may stop the growth of tumor cells by blocking some of the enzymes needed for cancer growth. NRG-LU003 was also to compare the chemotherapy drugs pemetrexed plus cisplatin, or carboplatin to test if chemotherapy would work equally, better or worse in these patients.
This study closed to patient enrollment on May 3, 2021 without meeting its original recruitment goal. NRG Oncology carefully monitors patient enrollment to studies to ensure the study can meet its goals to provide timely and meaningful results. Despite rigorous efforts to address low enrollment to the study, NRG has been unable to meet accrual goals and, unfortunately, it was not possible to complete the study. Study participants who were still on a study assigned drug at the time of its closure were allowed to continue receiving the drug as planned if they and their physician felt it was in the best interests of the participant. Once a participant completes all of their study medication all study data collection and procedures will stop, and the participant will continue their usual care with their doctor.
More information about this particular study is located on ClinicalTrials.gov
More information about NRG-LU003 can be found in the patient study brochure
At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.